APA (7th ed.) Citation

P, S., B, K., B, G., X, L., Z, X., WW, B., . . . MR, T. (2022). FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research, 28(9), 1759. https://doi.org/10.1158/1078-0432.CCR-21-3803

Chicago Style (17th ed.) Citation

P, Sharma, Kanapuru B, George B, Lin X, Xu Z, Bryan WW, Pazdur R, and Theoret MR. "FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 28, no. 9 (2022): 1759. https://doi.org/10.1158/1078-0432.CCR-21-3803.

MLA (9th ed.) Citation

P, Sharma, et al. "FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 28, no. 9, 2022, p. 1759, https://doi.org/10.1158/1078-0432.CCR-21-3803.